Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR8392887

— · cohortA1

9cac3914-2bac-5015-847e-fa3d64533e03

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
  • COAGULATION+0.400
  • MYOGENESIS+0.380
  • ANGIOGENESIS+0.340
  • APICAL_JUNCTION+0.320
  • COMPLEMENT+0.320
  • KRAS_SIGNALING_UP+0.310
  • NOTCH_SIGNALING+0.250
  • ADIPOGENESIS+0.230
  • HEDGEHOG_SIGNALING+0.230

Top 10 suppressed

  • E2F_TARGETS-0.550
  • G2M_CHECKPOINT-0.550
  • MYC_TARGETS_V1-0.470
  • MYC_TARGETS_V2-0.340
  • MTORC1_SIGNALING-0.330
  • UNFOLDED_PROTEIN_RESPONSE-0.250
  • ESTROGEN_RESPONSE_LATE-0.190
  • ANDROGEN_RESPONSE-0.180
  • DNA_REPAIR-0.180
  • MITOTIC_SPINDLE-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR26320070
bladder-landscape@3
——0.897
2d3119bbd-8c3d-4f95-863c-a04ae8b18eb9
colon-landscapes@1
——0.890
3TCGA-CN-6016-01A-11R-1686-07
head-neck@1
——0.889
4TCGA-BH-A0AZ-01A-21R-A12P-07
breast-umap@18
—A0.882
5TCGA-BH-A0DI-01A-21R-A12P-07
breast-umap@18
—A0.881
6TCGA-AC-A3HN-01A-11R-A213-07
breast-umap@18
—A0.881
7TCGA-38-4627-01A-01R-1206-07
lung-landscapes@6
—cohortA10.879
8SRR8518203
breast-umap@18
—A0.877
9SRR25043631
head-neck@1
——0.877
10SRR8518128
breast-umap@18
—A0.873

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.520Inavolisib— uncovered
COAGULATION0.400Binimetinib— uncovered
MYOGENESIS0.380Inavolisib— uncovered
ANGIOGENESIS0.340Remibrutinib— uncovered
APICAL_JUNCTION0.320Inavolisib— uncovered
COMPLEMENT0.320Inavolisib— uncovered
KRAS_SIGNALING_UP0.310Inavolisib— uncovered
NOTCH_SIGNALING0.250Inavolisib— uncovered
ADIPOGENESIS0.230Inavolisib— uncovered
HEDGEHOG_SIGNALING0.230Inavolisib— uncovered
IL2_STAT5_SIGNALING0.230Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.220Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.200Inavolisib— uncovered
ALLOGRAFT_REJECTION0.190Idelalisib— uncovered
UV_RESPONSE_DN0.190Inavolisib— uncovered
TGF_BETA_SIGNALING0.160Inavolisib— uncovered
BILE_ACID_METABOLISM0.130Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.120Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.120Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.110Inavolisib— uncovered